12 September 2019 - While chances of her leaked plan to force lower drug prices in the United States getting through the Republican-controlled Senate are extremely small, House Speaker Nancy Pelosi, D-California, put biosimilars, including insulins, into the national conversation this week.

The leaked plan proposes that the secretary of HHS should have the power to “to directly negotiate prices on the top 250 drugs with the greatest total cost to Medicare and the entire US health system without competition from at least [2] generic, biosimilar or interchangeable biologics on the market.”

Each year, the most expensive 250 drugs would be subject to review. Not only that, but the price would be available to all payers—not just Medicare, the document says.

Read Center for Biosimilars article